Hyundai ADM Bio

KOSDAQ-187660
KOSDAQ
Commercial Physical and Biological Research
Global Rank
#31806
Country Rank
#1949
Market Cap
37.04 M
Price
0.9
Change (%)
0.16%
Volume
270,743

Hyundai ADM Bio's latest marketcap:

37.04 M

As of 06/26/2025, Hyundai ADM Bio's market capitalization has reached $37.04 M. According to our data, Hyundai ADM Bio is the 31806th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 37.04 M
Revenue (ttm) 7.14 M
Net Income (ttm) -14,730,335.66
Shares Out 42.29 M
EPS (ttm) -0.35
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 09/09/2025
Market Cap Chart
Data Updated: 06/26/2025

Hyundai ADM Bio's yearly market capitalization.

Hyundai ADM Bio has seen its market value drop from ₩129.71 B to ₩37.04 M since 2021, representing a total decrease of 99.97% and an annual compound decline rate (CAGR) of 90.35%.
Date Market Cap Change (%) Global Rank
06/26/2025 ₩37.04 M -26.76% 31806
12/30/2024 ₩69.8 B 57.99% 28450
12/28/2023 ₩44.18 B 1.39% 30371
12/29/2022 ₩43.58 B -66.41% 29384
12/30/2021 ₩129.71 B 22589

Company Profile

About Hyundai ADM Bio Inc.

Hyundai ADM Bio Inc. is a leading contract research organization (CRO) specializing in clinical services across Asia. The company delivers comprehensive clinical development and pharmacovigilance solutions to support the pharmaceutical and biotechnology industries.

Core Services

  • Clinical Development Services – Including medical writing, clinical operations, late-phase studies, data management, biostatistics, and regulatory affairs.
  • Pharmacovigilance Services – Covering case processing, safety reporting, risk management plans, aggregate reporting, literature screening, and medical device vigilance.
  • Quality Assurance Services – Ensuring compliance and operational excellence.

Innovative Medical Solutions

The company also specializes in the development, manufacturing, and commercialization of medical microneedle patches, offering advanced therapeutic and diagnostic solutions.

Company Background

Originally established as ADM Korea Inc. in 2003, the company rebranded to Hyundai ADM Bio Inc. in September 2024. Headquartered in Seoul, South Korea, it continues to expand its footprint in the clinical research and medical technology sectors.

Frequently Asked Questions

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.